Item
SODIUM ASCORBATE (3180)
NLT 99.0% Sodium Ascorbate
Preservative
Attributes
- Gluten-free
- Halal
- Ingredient declaration
- Kosher
- PHO-free
- Ready-to-Eat (RTE)
- Vegan
- Non-GMO
Locations
| Location name | Address |
|---|---|
| CSPC WEISHENG PHARMACEUTICAL | No. 236 Huange Street High-Tech Development Zone Shijiazhuang, HE 50035 CHN |
| Jiangsu Jiangshan Pharmaceutical Co., Ltd. | No. 61, Jiangshan Road Jingjiang, JS 214500 CHN |
| Luwei Pharmaceutical Group Co., Ltd. | Shuangfeng Industrial Park Zibo City, SD 255190 CHN |
| Prinova USA | 6525 Muirfield Drive. Hanover Park, IL 60133 |
Documents
| Type | Location | File name | Effective | Expiration |
|---|---|---|---|---|
| HARPC Food Safety Plan (Item) | CSPC WEISHENG PHARMACEUTICAL | 3rd party-Haccp doc - Prinova.pdf | 7/28/2022 | 7/27/2025 |
| HACCP | CSPC WEISHENG PHARMACEUTICAL | 3rd party-Haccp doc - Prinova.pdf | 3/27/2024 | 3/27/2027 |
| Gluten | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | Allergen_Sodium Ascorbate_DSM 4.pdf | 7/8/2021 | 7/8/2022 |
| Allergens | Prinova USA | Allergens.pdf | 4/21/2017 | 4/21/2019 |
| Allergens | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | Allergens.pdf | 4/18/2023 | 4/17/2025 |
| Allergens | Luwei Pharmaceutical Group Co., Ltd. | Allergens.pdf | 5/4/2023 | 5/3/2025 |
| Allergens | CSPC WEISHENG PHARMACEUTICAL | Allergens.pdf | 7/31/2024 | 7/31/2026 |
| CoA Sample | Luwei Pharmaceutical Group Co., Ltd. | Approved COA Template - 2024-01-04T115050.843.pdf | 5/9/2023 | 5/8/2025 |
| CoA Sample | CSPC WEISHENG PHARMACEUTICAL | Approved COA Template - 2025-01-07T125408.786.pdf | 8/13/2023 | 8/12/2025 |
| CoA Sample | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | Approved COA Template - 2025-01-27T131730.990.pdf | 6/14/2024 | 6/14/2026 |
| WADA/NSF/NFL Statement | CSPC WEISHENG PHARMACEUTICAL | Banned Substance (6).pdf | 7/12/2024 | 7/12/2026 |
| Heavy Metal | CSPC WEISHENG PHARMACEUTICAL | Contaminants and Impurities - 2024-07-01T100200.784.pdf | 4/14/2024 | 4/14/2026 |
| Pesticide | CSPC WEISHENG PHARMACEUTICAL | Contaminants and Impurities - 2024-07-01T100200.784.pdf | 4/14/2024 | 4/14/2026 |
| Melamine | CSPC WEISHENG PHARMACEUTICAL | Contaminants and Impurities - 2024-07-08T163445.950.pdf | 4/14/2024 | 4/14/2025 |
| Residual Statement | CSPC WEISHENG PHARMACEUTICAL | Contaminants and Impurities - 2025-04-21T130304.046.pdf | 4/21/2025 | 4/21/2026 |
| Country of Origin | Prinova USA | Country of Origin.pdf | 4/21/2017 | 4/20/2020 |
| Country of Origin | Luwei Pharmaceutical Group Co., Ltd. | Country of Origin.pdf | 7/6/2023 | 7/5/2026 |
| Country of Origin | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | Country of Origin.pdf | 1/24/2024 | 1/23/2027 |
| Country of Origin | CSPC WEISHENG PHARMACEUTICAL | Country of Origin.pdf | 3/27/2024 | 3/27/2027 |
| Gluten | CSPC WEISHENG PHARMACEUTICAL | CSPC Weisheng - Sodium ascorbate - Allergen status & gluten-free.pdf | 4/15/2024 | 4/15/2026 |
| Product Specification Sheet | CSPC WEISHENG PHARMACEUTICAL | CSPC Weisheng - Sodium ascorbate - Spec.pdf | 3/27/2024 | 3/27/2027 |
| Dietary Supplement Questionnaire | CSPC WEISHENG PHARMACEUTICAL | Dietary Supplement Questionnaire.pdf | 8/24/2023 | 8/23/2024 |
| Label Sample | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | DSM - label for sodium ascorbate.pdf | 1/4/2022 | 1/4/2023 |
| GRAS/NDI/ODI Statement | CSPC WEISHENG PHARMACEUTICAL | FDA REGULATORY STATUS - Sodium ascorbate (3).pdf | 3/27/2024 | 3/27/2027 |
| HACCP Process Flow Diagram | CSPC WEISHENG PHARMACEUTICAL | Flow Chart - 2024-07-01T103653.670.pdf | 4/14/2024 | 4/14/2026 |
| FSVP Assessment Form | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | FSVP Assessment Form.pdf | 2/3/2021 | 2/3/2022 |
| FSVP Assessment Form | Luwei Pharmaceutical Group Co., Ltd. | FSVP Assessment Form.pdf | 7/2/2024 | 7/2/2025 |
| FSVP Assessment Form | CSPC WEISHENG PHARMACEUTICAL | FSVP Assessment Form.pdf | 8/9/2024 | 8/9/2025 |
| Gluten | Luwei Pharmaceutical Group Co., Ltd. | Gluten 1.pdf | 5/27/2020 | 5/27/2021 |
| GMO | Luwei Pharmaceutical Group Co., Ltd. | GMO - 2024-07-02T141615.180.pdf | 3/4/2024 | 3/4/2026 |
| GMO | CSPC WEISHENG PHARMACEUTICAL | GMO - 2025-03-05T123803.994.pdf | 3/5/2025 | 3/5/2027 |
| GMO | Prinova USA | GMO.pdf | 9/19/2016 | 9/19/2018 |
| Halal | CSPC WEISHENG PHARMACEUTICAL | Halal Certificate - 2024-03-27T110220.052.pdf | 7/28/2022 | 7/27/2026 |
| Halal | Prinova USA | Halal Certificate.pdf | 9/8/2016 | 9/7/2018 |
| Ingredient Statement | Prinova USA | Ingredient % Breakdown.pdf | 10/19/2015 | 10/18/2016 |
| Item Questionnaire | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | Item Questionnaire.pdf | 1/22/2021 | 1/22/2022 |
| Item Questionnaire | Luwei Pharmaceutical Group Co., Ltd. | Item Questionnaire.pdf | 7/22/2022 | 7/21/2025 |
| Item Questionnaire | CSPC WEISHENG PHARMACEUTICAL | Item Questionnaire.pdf | 10/21/2024 | 10/21/2027 |
| Kosher | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | Kosher Certificate - 2024-01-15T115545.118.pdf | 12/27/2023 | 12/7/2024 |
| Kosher | Luwei Pharmaceutical Group Co., Ltd. | Kosher Certificate - 2024-05-10T143532.564.pdf | 3/25/2024 | 3/25/2025 |
| Kosher | CSPC WEISHENG PHARMACEUTICAL | Kosher Certificate - 2024-09-16T112018.958.pdf | 8/27/2024 | 8/31/2025 |
| Kosher | Prinova USA | Kosher Certificate.pdf | 3/14/2017 | 12/31/2017 |
| Label Sample | CSPC WEISHENG PHARMACEUTICAL | Label (94).pdf | 1/1/2024 | 12/31/2024 |
| Lot Code | Prinova USA | Lot Code Explanation.pdf | 2/22/2017 | 2/22/2020 |
| Halal | Luwei Pharmaceutical Group Co., Ltd. | Luwei Pharmaceutical - Halal (Jun 19, 2024) (4).pdf | 6/19/2022 | 6/19/2024 |
| National Bioengineered Food Disclosure Standard (Simplified) | Luwei Pharmaceutical Group Co., Ltd. | National Bioengineered Food Disclosure Standard (Simplified).pdf | 6/2/2021 | 6/1/2024 |
| National Bioengineered Food Disclosure Standard (Simplified) | CSPC WEISHENG PHARMACEUTICAL | National Bioengineered Food Disclosure Standard (Simplified).pdf | 9/5/2024 | 9/5/2027 |
| Nutrition | Luwei Pharmaceutical Group Co., Ltd. | Nutrition.pdf | 7/6/2023 | 7/5/2026 |
| Nutrition | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | Nutrition.pdf | 10/20/2023 | 10/19/2026 |
| Nutrition | CSPC WEISHENG PHARMACEUTICAL | Nutrition.pdf | 3/27/2024 | 3/27/2027 |
| Sewage Statement | CSPC WEISHENG PHARMACEUTICAL | Organic Compliance - 2025-04-21T131008.716.pdf | 4/21/2025 | 4/21/2027 |
| Irradiation Status Statement | CSPC WEISHENG PHARMACEUTICAL | Organic Compliance (51).pdf | 2/9/2023 | 2/8/2025 |
| Natural | CSPC WEISHENG PHARMACEUTICAL | Organic Compliance (91).pdf | 2/9/2023 | 2/9/2024 |
| Organic | CSPC WEISHENG PHARMACEUTICAL | Organic Compliance (91).pdf | 2/9/2023 | 2/9/2024 |
| EtO Statement | CSPC WEISHENG PHARMACEUTICAL | Organic Compliance (92).pdf | 2/9/2023 | 2/8/2025 |
| Food Contact Packaging Certificate of Compliance | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | Packaging Declaration - 2023-09-20T103045.622.pdf | 3/12/2021 | 3/12/2024 |
| Lot Code | Luwei Pharmaceutical Group Co., Ltd. | Packaging Declaration - 2024-07-02T135904.983.pdf | 3/4/2024 | 3/4/2027 |
| Lot Code | CSPC WEISHENG PHARMACEUTICAL | Packaging Declaration - 2024-07-12T135458.818.pdf | 4/14/2024 | 4/14/2027 |
| Food Contact Packaging Certificate of Compliance | CSPC WEISHENG PHARMACEUTICAL | Packaging Declaration - 2025-02-03T161019.633.pdf | 4/14/2024 | 4/14/2026 |
| Label Sample | Luwei Pharmaceutical Group Co., Ltd. | Packaging Declaration - 2025-03-26T103219.133.pdf | 3/26/2025 | 3/26/2026 |
| Sewage Statement | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | PDFCOMPOUNDFood_000000000005015846_en 1.pdf | 3/3/2021 | 3/3/2023 |
| HACCP | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | PDFCOMPOUNDFood_000000000005015846_en 1.pdf | 3/3/2021 | 3/2/2024 |
| HACCP Process Flow Diagram | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | PDFCOMPOUNDFood_000000000005015846_en 1.pdf | 3/3/2021 | 3/3/2023 |
| Vegan/Vegetarian Statement | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | PDFCOMPOUNDFood_000000000005015846_en 2.pdf | 3/3/2021 | 3/3/2023 |
| Lot Code | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | Product Data Sheet - 2024-01-17T153701.638.pdf | 1/4/2022 | 1/3/2025 |
| California Prop. 65 | CSPC WEISHENG PHARMACEUTICAL | Product Data Sheet - 2024-06-10T153708.069.pdf | 4/14/2024 | 4/14/2026 |
| Ingredient Statement | CSPC WEISHENG PHARMACEUTICAL | Product Data Sheet - 2024-07-01T103034.084.pdf | 4/14/2024 | 4/14/2025 |
| Ingredient Statement | Luwei Pharmaceutical Group Co., Ltd. | Product Data Sheet - 2024-07-02T152340.202.pdf | 3/4/2024 | 3/4/2025 |
| Ingredient Statement | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | Product Data Sheet (38).pdf | 1/4/2022 | 1/4/2023 |
| Heavy Metal | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | Product Data Sheet (48).pdf | 11/9/2021 | 11/9/2023 |
| California Prop. 65 | Luwei Pharmaceutical Group Co., Ltd. | Prop 65 - 2024-11-19T141158.425.pdf | 11/15/2023 | 11/14/2025 |
| California Prop. 65 | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | Prop 65 (32).pdf | 4/14/2022 | 4/13/2024 |
| Animal Testing Statement | CSPC WEISHENG PHARMACEUTICAL | RE_ CSPC Weisheng - Sodium Ascorbate docs 6 (2).pdf | 6/21/2021 | 6/21/2024 |
| Vegan/Vegetarian Statement | CSPC WEISHENG PHARMACEUTICAL | Regulatory Information Sheet - 2024-07-01T095534.851.pdf | 4/14/2024 | 4/14/2026 |
| BSE - TSE | CSPC WEISHENG PHARMACEUTICAL | Regulatory Information Sheet - 2024-07-08T163306.041.pdf | 4/14/2024 | 4/14/2027 |
| Safety Data Sheet (SDS) | CSPC WEISHENG PHARMACEUTICAL | SDS - 2024-11-22T143510.708.pdf | 8/15/2024 | 8/15/2027 |
| Safety Data Sheet (SDS) | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | SDS - 2025-01-07T144249.601.pdf | 6/14/2024 | 6/14/2027 |
| Safety Data Sheet (SDS) | Luwei Pharmaceutical Group Co., Ltd. | SDS - 2025-03-03T120701.821.pdf | 3/3/2025 | 3/2/2028 |
| Safety Data Sheet (SDS) | Prinova USA | SDS.pdf | 4/3/2015 | 4/2/2017 |
| HACCP Process Flow Diagram | Luwei Pharmaceutical Group Co., Ltd. | Sodium Ascorbate (626) Luwei - flow chart.pdf | 3/31/2022 | 3/30/2024 |
| Phthalate Esters Letter | CSPC WEISHENG PHARMACEUTICAL | Sodium Ascorbate (626) Weisheng - Contaminants & Impurities (CN)-v3 amended (12).pdf | 6/30/2023 | 6/29/2024 |
| No Animal Ingredient Statement | CSPC WEISHENG PHARMACEUTICAL | Sodium Ascorbate (626) Weisheng - Regulatory Information Sheet (CN) v3 (10).pdf | 6/30/2023 | 6/29/2024 |
| Label Claims | CSPC WEISHENG PHARMACEUTICAL | Sodium Ascorbate (626) Weisheng - Regulatory Information Sheet (CN) v3 (8).pdf | 6/30/2023 | 6/29/2025 |
| Label Guidance | CSPC WEISHENG PHARMACEUTICAL | Sodium Ascorbate (626) Weisheng - Regulatory Information Sheet (CN) v3 (8).pdf | 6/30/2023 | 6/29/2025 |
| GMO | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | Sodium Ascorbate 626 - DSM - Dosseir 5015846_PDF.pdf | 11/6/2020 | 11/6/2022 |
| Product Specification Sheet | Luwei Pharmaceutical Group Co., Ltd. | Specification - Factory - 2024-07-02T135551.161.pdf | 3/4/2024 | 3/4/2027 |
| Shelf Life | CSPC WEISHENG PHARMACEUTICAL | Specification - Factory - 2024-07-08T163634.844.pdf | 4/14/2024 | 4/14/2027 |
| Product Specification Sheet | Prinova USA | Specification - Factory.pdf | 7/7/2015 | 7/6/2018 |
| Suitability Requirements | Luwei Pharmaceutical Group Co., Ltd. | Suitability Requirements.pdf | 7/6/2023 | 7/5/2026 |
| Suitability Requirements | Jiangsu Jiangshan Pharmaceutical Co., Ltd. | Suitability Requirements.pdf | 10/18/2023 | 10/17/2026 |
| Suitability Requirements | CSPC WEISHENG PHARMACEUTICAL | Suitability Requirements.pdf | 3/27/2024 | 3/27/2027 |
